about
The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside ReviewDiabetes DyslipidemiaCardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?Filling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial EvidenceA Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes MellitusVitamin D and Diabetic Complications: True or False Prophet?Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular TrialsDogs Can Be Successfully Trained to Alert to Hypoglycemia Samples from Patients with Type 1 Diabetes.A Practical Approach to Glucose Abnormalities in Cystic FibrosisStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseA Practical Approach to Gastrointestinal Complications of DiabetesCanagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 DiabetesLipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal ImpairmentInitiation and Intensification Strategies in Type 2 Diabetes Management: A Comparison of Basal Plus and Premix RegimensClinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature ReviewSleep Optimization and Diabetes Control: A Review of the LiteratureLack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review.The Impact of Frequency and Tone of Parent-Youth Communication on Type 1 Diabetes Management.Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes.Assessment of the clinical outcome of a symptom-based outpatient hyperglycemia protocolInitial experience and evaluation of reusable insulin pen devices among patients with diabetes in emerging countries.Dialing torque preferences of people with diabetes when using insulin pens: a pilot studySimvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures.Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.Experiences of People with Diabetes by Payer Type: An Analysis of the Roper Diabetes Data Set.Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-AnalysisInsulin Degludec in Clinical Practice: A Review of Japanese Real-World Data.Indian Injection Technique Study: Population Characteristics and Injection PracticesIndian Injection Technique Study: Injecting Complications, Education, and the Health Care ProfessionalAdding Prandial Insulin to Basal Insulin Plus Oral Antidiabetic Drugs in Chinese Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Single-Arm Study.The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study.Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program.Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine.Resistance Training for Glycemic Control, Muscular Strength, and Lean Body Mass in Old Type 2 Diabetic Patients: A Meta-Analysis.Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.Comment on the New Indian Injection Technique Recommendations: Critical Appraisal of the Real-World Implementation of the Current Guidelines.
P1433
Q24563917-1C3CD6E7-5A19-4B8D-8109-FBD5905DF7A3Q26750905-71619D6A-1065-43D1-91EE-8A6438F89B67Q26752255-5BAF89DD-8296-4203-A44A-467C1F702CC9Q26752669-E41CCB49-75B6-47CB-9A6B-1848AB50C4A5Q26765155-F166D8D7-CB26-4244-B3F4-868019E012DDQ26766181-F73863A8-E35B-4279-8872-C1ABBAD06804Q26767164-76C576AA-32E4-4C5F-922C-26AF79CD2A8AQ27339331-4484B051-9AD7-4A2D-A76C-7CF105135F10Q28067394-09F02C76-FA1B-49A3-B415-7F4FB7330B1BQ28069065-AB06562F-4DC0-4807-9912-87A323937FF0Q28071949-BBB46CA5-53AD-4E59-A9ED-49A5CDDDF715Q28072339-D5E5579C-F62D-45FB-96C0-2072A275494BQ28072729-E197053F-EC33-4295-82C2-30CE6EC423B6Q28075368-87549BD2-6245-4EB7-B119-B229D7BCE996Q28077688-CD7A58C9-FAC6-4BA0-9152-AB25325E074AQ28079191-1FA3A25C-72B1-4A83-BFDB-52174C918186Q28395977-7DEEFDB7-5663-4B50-BEAC-5634733704A1Q30240040-C727AD72-26C0-4D09-A84E-0FBBB8F7CA9BQ30252642-B5D2CBD3-2F00-418C-A4D0-0E2FD3C6AA2FQ30491380-638C1C13-25BE-4D25-9055-6255B238272CQ30502892-E0AC19A8-06D6-4F88-8019-D36921CC8BFAQ30609075-687ED5DB-32C2-4FDF-A802-3C738AF51FD6Q30632087-5E29D27D-1CFB-440D-BB78-1FC5B5401F9DQ30829288-590EDD85-B4ED-498A-8E74-ED285B14FB77Q30877953-9A9969DB-C6E9-445F-BB15-7B4DF8BB51FAQ30956122-F977AAA7-9001-44BD-B1C6-C8004058C8ECQ31046934-D6D9D9C5-BEF6-4A9A-A67D-D12DD33EEB87Q31140045-E94EBD57-6B65-4C70-A10F-8BF24903905BQ31154873-A912A397-60A2-47C6-836A-59EFF0066A61Q33732565-626E3FB0-74A8-4E42-A831-F5E7E5D0A814Q33732571-598F08EF-0700-4348-8915-BCC8E827643AQ33732577-990236A4-ED8B-4645-A83E-427DA38D14C9Q33732583-F39D0780-4D44-41D2-B38F-5319E4B7674CQ33732588-02CDB2BD-0C0C-4619-A9E1-7F0EBE33A1D3Q33732593-E4E3F8B6-0362-4F8E-BEB8-7B3792760D34Q33732598-7342B09E-D732-4D0C-9CF0-7651FE3B3CEEQ33732607-0311F1A8-E0FF-4BC5-81D3-3F145020348EQ33732617-50D330F8-0ADB-43BB-B04E-27F423AF35E4Q33732627-092191A4-17D8-4B33-B4C3-876B69932599Q33732634-CEBAC6F3-25A4-4824-B4D5-98DD6FF2CC5C
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Adis, Springer Healthcare
@nl
wissenschaftliche Fachzeitschrift
@de
name
Diabetes Therapy
@ast
Diabetes Therapy
@en
Diabetes Therapy
@es
Diabetes Therapy
@it
Diabetes Therapy
@nl
type
label
Diabetes Therapy
@ast
Diabetes Therapy
@en
Diabetes Therapy
@es
Diabetes Therapy
@it
Diabetes Therapy
@nl
prefLabel
Diabetes Therapy
@ast
Diabetes Therapy
@en
Diabetes Therapy
@es
Diabetes Therapy
@it
Diabetes Therapy
@nl
P31
P3181
P1055
P1156
19700175906